Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Review Article
Authors: Tao, Shuqia; 1 | Fan, Wenyuana; 1 | Liu, Jinmengb; 1 | Wang, Tongc | Zheng, Haoninga | Qi, Gaoxiud | Chen, Yanchunb; e | Zhang, Haoyunb | Guo, Zhangyua; b; * | Zhou, Fenghuaa; b; *
Affiliations: [a] Department of Pathology, School of Basic Medical Sciences, Weifang Medical University, Weifang, Shandong Province, China | [b] Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang, Shandong Province, China | [c] Department of Neurosurgery, Wei Fang People’s Hospital, Weifang, Shandong Province, China | [d] Department of Pathology, Affiliated Hospital, Weifang Medical University, Weifang, Shandong Province, China | [e] Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang, Shandong Province, China
Correspondence: [*] Correspondence to: Zhangyu Guo and Fenghua Zhou, Department of Pathology, Weifang Medical University, Weifang 261053, Shandong Province, China. E-mails: guozhy@wfmc.edu.cn, zhoufh@wfmc.edu.cn.
Note: [1] These authors contributed equally to this work.
Abstract: Alzheimer’s disease (AD) is currently the most prevalent neurological disease, and no effective and practical treatments and therapies exist. The nucleotide-binding oligomerization domain-, leucine-rich repeat-, and pyrin domain- containing receptor 3 (NLRP3) inflammasome is vital in the human innate immune response. However, when the NLRP3 inflammasome is overactivated by persistent stimulation, several immune-related diseases, including AD, atherosclerosis, and obesity, result. This review will focus on the composition and activation mechanism of the NLRP3 inflammasome, the relevant mechanisms of involvement in the inflammatory response to AD, and AD treatment targeting NLRP3 inflammasome. This review aims to reveal the pathophysiological mechanism of AD from a new perspective and provide the possibility of more effective and novel strategies for preventing and treating AD.
Keywords: Alzheimer’s disease, amyloid-β, inhibitors, NLRP3 inflammasome, tau, treatment
DOI: 10.3233/JAD-230567
Journal: Journal of Alzheimer's Disease, vol. 96, no. 4, pp. 1383-1398, 2023
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl